Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.
Pinpointing the expiration date of drug patents can make filing taxes look like child's play. Each drug has wide ranging intellectual property, with timelines that are ever-changing. That said, here’s a list of 26 drugs that will probably go off patent in 2018.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
This will be a year in which generic drugmakers will have plenty of fodder - more than two dozen major drugs are going off-patent in 2016.
Despite the influx of recent, positive news from Bristol-Myers Squibb, CEO Lamberto Andreotti remained a bit cagey during today’s JP Morgan presentation about the company’s plan this year to recover from major drugs like Abilify and Baraclude going off-patent. The past three weeks alone have been quite bullish for the pharma giant: With the “earlier-than-expected” approval of Opdivo for […]
Takeda announced positive late-stage results for its new type 2 diabetes drug, fasiglifam (TAK-875), the first GPR40 agonist to reach late-stage development. Fasiglifam has the potential to be a compelling therapeutic option and will likely be investigated for use in combination therapy, given its unique mechanism of action. The Japanese drug maker is in desperate […]